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ABSTRACT
Purpose. To examine the usefulness of trimodality ther-
apy in patients with clinical T3 or T4 (cT3–4) locally
advanced non–small cell lung cancer (LA-NSCLC).
Methods. Between 1997 and 2009, a total of 76 LA-NSC
LC patients with cT3–4 underwent surgery. Among them,
36 patients underwent induction chemoradiotherapy with
docetaxel and cisplatin plus concurrent radiation followed
by surgery (IC group). The other 40 patients initially
underwent surgery (IS group). The outcomes of the IC and
IS groups were then investigated. To minimize possible
biases caused by confounding treatment indications, we
performed a retrospective cohort analysis by applying a
propensity score (PS). Patients were divided into three
groups according to PS tertiles, and comparisons between
the IC and IS groups were made by PS tertile-stratified Cox
proportional hazard models.
Results. For the entire cohort, which had a median follow-
up duration of 48 months, the 3- and 5-year overall sur-
vival rates were 83.8 and 78.9%, respectively, in the IC
group, versus 66.8 and 56.5%, respectively, in the IS group
(P = 0.0092). After adjustments for potentially con-
founding variables, the IC group continued to have a
significantly longer overall survival than the IS group
(P = 0.0045). In addition, when the analysis was limited to
52 patients with cT3–4N0 or N1 disease, the IC group had
a significantly longer overall survival than the IS group
after adjustments for confounding variables (P = 0.019).
Conclusions. Our study indicates that trimodality therapy
is highly effective in patients with cT3–4 LA-NSCLC.
Lung cancer continues to be a major cause of cancer
mortality worldwide. Almost half of all patients develop
inoperable stage IV disease with metastasis to distant sites,
and a quarter of all patients are diagnosed after the cancer
has already spread to regional lymph nodes or directly
beyond the primary site, resulting in a stage II or III dis-
ease.1 For stage II or III non–small cell lung cancer
(NSCLC), surgical resection remains an important part of
treatment.2
The N and T statuses determine the degree of local
disease extension. N2 or N3 (N2–3) disease and T3 or T4
(T3–4) disease are considered locally advanced (LA) dis-
eases. An N2–3 status generally indicates a need for
definitive chemoradiotherapy (CRT) or induction CRT
followed by surgery, rather than initial surgery.3 On the
other hand, initial surgery is generally the treatment of
choice for N0 or N1 (N0–1) disease. Regarding the T
factor, whereas T3 tumors are basically candidates for
initial surgery, such treatment is not recommended for T4
tumors, in principle, because of the large risk of an
incomplete resection, especially when the tumors have
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highly invaded important structures. However, complete
resections may be possible in patients with limited invasion
of some structures including the carina, left atrium, supe-
rior vena cava, or pulmonary artery.2 In addition, T4
staging tends to be clinically overstaged, rather than un-
derstaged.4 Considering these factors, clinical T4 (cT4)
disease is not a contraindication for surgery.
In the literature, the 5-year survival rate of patients with
T3 disease who were treated with initial surgery has been
reported to be 18–37%.5–7 Thus, the clinical outcome
remains unsatisfactory, especially in patients with incom-
plete resection. We have used induction chemotherapy
or CRT followed by surgery for the treatment of N2–3
LA-NSCLC disease since 1995.8, 9 Trimodality therapy for
stage III NSCLC has yielded a 3-year survival rate of more
than 60%, which seems to be superior to the outcome of
reported T3 disease even though N2–3 diseases were inclu-
ded in our study cohort. These results strongly suggested the
usefulness of trimodality therapy for LA-NSCLC including
T3 disease. Considering these, whereas the use of induction
CRT for LA-NSCLC remains controversial except in
patients with superior sulcus tumor, we have applied tri-
modality therapy for less advanced diseases including
T3N0M0 and T3N1M0 based on the physician’s discretion
in individual cases.10
As evidence regarding trimodality therapy for clinical
T3 or T4 (cT3–4) without N2–3 disease in randomized
controlled trials remains scarce, second-best evidence from
retrospective studies comparing two approaches should be
considered.2 In the present retrospective study, we exam-
ined the usefulness of trimodality therapy for patients with
cT3–4 LA-NSCLC, compared with patients who under-
went initial surgery. One serious concern with this
approach is that the results may be biased by confounding
indications. To avoid this possibility, we conducted a ret-
rospective cohort analysis by applying a propensity score
(PS) analysis in addition to the usual cohort analysis.
PATIENTS AND METHODS
Patient Selection and Evaluation
The records of 76 consecutive patients with cT3–4
invasive NSCLC who underwent pulmonary resection with
nodal dissection between March 1997 and October 2009 at
Okayama University Hospital, Okayama, Japan, were
reviewed. The patient characteristics are shown in Table 1.
Patients whose cT status was determined by tumor size
more than 7 cm or presence of satellite nodules were
excluded from this study. Among cN2 patients, pathologic
N2 was confirmed in 8 patients who underwent a medias-
tinoscopy. Among 76 patients, 36 patients received
induction CRT before resection (IC group), and 40 patients
underwent initial surgery without receiving induction CRT
(IS group). All 8 patients who had confirmed pathologic
mediastinal nodal metastasis were treated with induction
CRT followed by surgery. The International Association of
the Study of Lung Cancer tumor, node, metastasis system
for NSCLC, 7th edition, was used for disease staging.11
Clinical stage was determined by chest radiography,
bronchoscopy, computed tomography (CT) of the chest and
upper abdomen, magnetic resonance imaging (MRI) of the
brain, and a radionuclide bone scan or 18F-fluorodeoxy-
glucose positron emission tomography (PET)/CT scan. The
institutional review board approved the study, and
informed consent was obtained from all the patients.
Induction CRT
The application of trimodality therapy was left to the
physician’s discretion. Basically, induction CRT was
administered to patients who had mediastinal nodal
metastases confirmed by a mediastinoscopy or large and
invasive tumors that would have made the achievement of
a complete resection with a pathologic safety margin dif-
ficult. The criteria and treatment regimen for induction
CRT have been previously described.9 In brief, docetaxel
(40 mg/m2) was administered intravenously followed by
cisplatin (40 mg/m2) before radiotherapy on days 1 and 8.
The chemotherapy was repeated at a 3- or 4-week interval.
Radiotherapy was started on the first day of chemotherapy
and total radiation dose of 46 gray (Gy) was planned, in
principle, using a conventional fractionation (2 Gy/day).
Dose escalation of the radiotherapy was allowed for poorly
responding tumors up to 60 Gy.
After induction CRT, the patients were restaged and
those without progressive disease were scheduled to
receive surgery within 6 weeks of the completion of the
induction therapy. The radiologic response of lesions was
classified into four categories as described in previous
study: complete response, partial response, stable disease,
and progressive disease.9,12 The pathologic response to
induction CRT was classified into three groups: pathologic
complete response, pathologic major response, and patho-
logic minor response.13
Surgical Resection, Adjuvant Treatment, and Follow-up
The surgical procedure was determined on the basis of
the extent of disease. Although a lobectomy was preferred,
a bilobectomy, sleeve resection, or pneumonectomy was
performed in cases requiring such procedures because of
the location of the primary tumor or metastatic nodal
invasion. All the patients underwent complete ipsilateral
mediastinal and subcarinal nodal dissection. For cN3 dis-
ease (n = 4), the contralateral hilar (n = 1) or ipsilateral
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supraclavicular (n = 3) lymph nodes were dissected
according to the initial disease extent. Resection with
reconstruction of the chest wall or major vessels was per-
formed, if necessary. In the IC group, the bronchial stump
was covered with pericardial fat tissue or an intercostal
muscle pedicle. When a sleeve resection was performed,
the greater omentum was used to wrap the anastomosis.
Postoperative treatment was left to the physician’s discre-
tion. Follow-up protocol after surgery is as follows: chest
and abdominal CT or PET/CT scan and enhanced brain
MRI were repeated every 3 months for 2 years. From 3 to
5 years, these image analyses were repeated every
6 months. After 5 years, chest X-ray was repeated every
year.
Statistical Methods
We calculated the PS by logistic regression based on
available factors that were considered to be potentially
associated with patient selection and the pscore command
in Stata, version 11 (StataCorp, College Station, TX).
Seven such factors that were included in the PS calculation
were age, sex, histology, performance status, clinical stage,
operation type, year of treatment (Supplementary Material 1).
After the PS calculation, the subjects were divided into 3
groups according to the PS tertile to sustain comparability
between the IC and the IS group within each stratum.
In this study, overall survival (OS) was defined as the
primary end point and disease-free survival (DFS) as
the secondary end point. OS and DFS were calculated from
the date of initial treatment until the date of death or the
last follow-up for OS and until confirmed disease recur-
rence by cross-sectional imaging studies or death for DFS.
We used the PS to control potential confounding by
treatment indication for the induction CRT on survival. We
compared end points for the IC and IS groups in three
patterns: (1) comparison using all the patients in the cohort
(n = 76), (2) comparison among cN0–1 patients (n = 52),
and (3) comparison of a selected cohort in which IC
patients were individually matched with IS patients by PS
TABLE 1 Patient characteristics (unadjusted)
Variable IC (n = 36) IS (n = 40) P
Age, y, median (range) 58 (33–74) 68 (48–81) 0.0005
Sex, M/F 30/6 35/5 0.75
Histology, Sq/Ad/AdSq/LC 17/17/1/1 22/15/1/2 0.80
Performance status, 0/1 26/10 31/9 0.61
Period of treatment, 1997–2003/2004–2009 14/22 23/17 0.10
c stage T3 N0 5 18 \0.001
IIB T3 N1/N2 3/7 11/4
IIIA T4 N0/N1 3/5 5/2
IIIB T3 N3 4 0
T4 N2 9 0
Involved structures
cT3 Chest wall 12 28a
Parietal pleura 5 12
Rib or muscle 7 16
Diaphragm 0 3a
Pericardium 1 4a
Mediastinal pleura 3 1
\2 cm carina 3 1
cT4 Atrium 1 0
Great vessel 13a 7
Esophagus 2a 0
Vertebral body 1a 0
Carina 2 0
Superior sulcus 4 1
IC induction chemoradiotherapy, IS initial surgery, Sq squamous cell carcinoma, Ad adenocarcinoma, AdSq adenosquamous carcinoma, LC large
cell carcinoma
a Multiple structures were involved: chest wall with diaphragm (n = 1), with pericardium (n = 2), diaphragm with pericardium (n = 1), great
vessel with esophagus (n = 1), with vertebral body (n = 1)
Induction CRT for cT3–4 NSCLC 2687
in all the patients (n = 32), and cN0–1 patients (n = 24).
For pattern 1 and 2, the IC and IS groups were compared
by a stratified logrank test and a stratified multivariate Cox
proportional hazard model with PS tertile as a stratification
factor. For pattern 3, the IC and IS groups were compared
by usual logrank test and multivariate Cox proportional
hazard model.
The baseline characteristics of the IC and IS groups
were compared by the Wilcoxon rank sum test for con-
tinuous variables and the Fisher’s exact test for categorical
variables, as appropriate. Data were analyzed by Stata,
version 11. P values of less than 0.05 were considered
significant for comparison of characteristics. We applied
P value less than 0.01 as significant for survival analysis to
avoid inflation of alpha error by multiple comparisons.
RESULTS
Patient Characteristics
Between March 1997 and October 2009, a total of 76
LA-NSCLC patients with cT3–4 disease underwent surgi-
cal resection. The patient characteristics stratified
according to therapeutic modality are shown in Table 1. A
difference in the patient backgrounds was noted for age and
clinical stage. The median age was significantly younger
and the clinical stage was significantly higher in the IC
group than in the IS group (age, P = 0.0005; stage,
P \ 0.001).
Toxicities and Response to Induction CRT
Out of the 36 patients in the IC group, 23 completed the
planned CRT. The toxicities were similar to those descri-
bed in our previous report.9 The chemotherapy dose was
modified because of toxicity in 12 patients. The total
radiation dose was 20 Gy in 1 patient, 40 Gy in 8 patients,
46 Gy in 19 patients, and more than 50 Gy in 8 patients.
The clinical response to induction therapy was partial
response in 25 patients, stable disease in 11 patients, and
complete response or progressive disease in none. The
pathologic response in the resected specimens was esti-
mated. Nineteen patients (53%) exhibited a pathologic
complete response, 17 patients (47%) exhibited a patho-
logic major response, and none of the patients exhibited a
pathologic minor response.
Surgical Resection, Postoperative Complications,
and Adjuvant Treatment
The surgical procedures and postoperative complica-
tions are shown in Table 2. All 76 patients underwent
surgical resection. In the IC group, all the patients under-
went complete tumor resection. In the IS group, 37 (93%)
of the 40 patients underwent complete tumor resection; two
patients had pleural dissemination that was diagnosed
pathologically after surgery, and one patient had a micro-
scopically positive surgical margin.
One patient in the IS group died after a left pneumonectomy
because of acute respiratory failure. Pulmonary complications
were the most common type of postoperative complication in








Sleeve lobectomy 7 1
Bilobectomy 5 1
Pneumonectomy 3 4
Combined resection, yes/no 27/9 35/5 0.24
Chest wall 12a 25a
Parietal pleura 8 10
Rib or muscle 4 15
Diaphragm 0 6a
Pericardium 0 5a
Mediastinal pleura 6 1
Atrium 1 0
Great vessel 7a 5a
Recurrent nerve 1a 0
Esophagus 1 0
Carina 1 0






Hemorrhage, reoperation 0 1
Chylothorax 1 0
Bronchopleural fistula 1 0
Atrial arrhythmia 2 2
Hoarseness 2 4
Effusion 0 2
Brachial plexus palsy 1 0
Radiation pneumonitis 4 0
Postoperative morality 0 1
IC induction chemoradiotherapy, IS initial surgery
a Multiple structures were resected; (Induction CRT group) chest
wall with great vessel (n = 1), with recurrent nerve (n = 1), (Initial
surgery group) chest wall with diaphragm (n = 1), with pericardium
(n = 2), diaphragm with pericardium (n = 2), chest wall with dia-
phragm and great vessel (n = 1)
b The number of each event was described
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both groups. No significant difference in the rate of postop-
erative complications was observed between the groups.
In the IC group, 14 patients underwent adjuvant che-
motherapy. In the IS group, 14 patients underwent adjuvant
chemotherapy, seven patients underwent adjuvant radio-
therapy, three patients underwent adjuvant CRT.
Survival and Relapse Pattern
At a median follow-up period of 48 months, five patients
in the IC group and 13 patients in IS group had died of
NSCLC. One patient in the IC group and three patients in the
IS group had died of other causes. Seven patients in the IC
group and 17 patients in the IS group had experienced a
disease relapse. The disease recurrence patterns were classi-
fied as local sites (surgical margin, intrapulmonary, regional
lymph node, and pleural cavity) and distant sites. The initial
recurrent patterns were as follows: in the IC group, 1 patient
(3%) developed a recurrence at local site, 3 patients (8%)
developed recurrences at distant sites, and 3 patients (8%)
developed recurrences at both sites; in the IS group, 8 patients
(20%) developed recurrences at local sites, 5 patients (13%)
developed recurrences at distant sites, and 4 patients (10%)
developed recurrences at both sites.
In analysis pattern 1 with the unadjusted model, the 3-
and 5-year OS rates were 83.8 (95% confidential interval
[CI] 65.3–92.9) and 78.9% (95% CI 58.2–90.1) in the IC
group, versus 66.8 (95% CI 46.6–80.8) and 56.5% (95% CI
35.1–73.2) in the IS group (Fig. 1). The patients in the IC
group showed significantly longer OS and DFS times than
those in the IS group (OS, P = 0.0092; DFS, P = 0.0037).
Subset analyses identified several factors that were related
to a favorable outcome: the initial disease stage, sex, his-
tology, and pathologic response. Only the use of induction
therapy was significantly associated with the outcome.
There was no significant difference in OS and DFS
between those with or without adjuvant therapy in both the
IC and IS groups.
The comparison of the characteristics between the IC
and IS groups according to the PS tertile indicated an
equivalent distribution of the background characteristics
(Supplementary Material 2). When the PS was taken into
consideration, the patients in the IC group continued to
exhibit a significantly longer OS than those in the IS group
according to a stratified logrank test (P = 0.0045). A
multivariate analysis showed a significantly better outcome
in the IC group (hazard ratio [HR], 0.068; 95% CI
0.013–0.35; P = 0.001) (Supplementary Material 3).
a bFIG. 1 Kaplan-Meier curves
showing the unadjusted a OS and
b DFS rates for patients in the IC
and IS groups
a bFIG. 2 Kaplan-Meier curves
showing the unadjusted a OS
and b DFS rates for patients
with cT3–4 and cN0–1 disease
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The OS and DFS curves for 52 patients with clinical N0
or N1 (cN0–1) (analysis pattern 2) are shown in Fig. 2. The
3- and 5-year OS rates were both 92.3% (95% CI
56.6–98.9) in the IC group (n = 16) and were 67.7 (95%
CI 46.6–81.9) and 56.4% (95% CI 33.9–73.8) in the IS
group (n = 36), respectively. In this cohort, the OS and
DFS times in the IC group were significantly longer than
those in the IS group (OS, P = 0.027; DFS, P = 0.017). In
addition, the PS values were calculated in this cohort, and
survivals were analyzed after stratification according to the
PS tertile (Supplementary Material 1). A comparison of the
characteristics between the IC and IS groups according to
the PS tertile is shown in Supplementary Material 4. When
the PS was taken into the consideration, the patients in the
IC group continued to exhibit a significantly longer OS
than those in the IS group (a stratified logrank test,
P = 0.019). A multivariate analysis continued to exhibit a
significantly better outcome in the IC group in this cohort
(HR, 0.068; 95% CI 0.00043–0.28; P = 0.006, Supple-
mentary Material 5).
PS Matching Analysis (Analysis Pattern 3)
Among all 76 patients, 32 patients were extracted from
each group using PS matching. The patient characteristics
were matched as shown in Table 3. After adjustments for
TABLE 3 Patient characteristics of PS matched cohort
Variable IC (n = 16) IS (n = 16) P
Age, y, median (range) 64 (51–74) 64 (48–75) 0.82
Sex, M/F 13/3 13/3 1.00
Histology, Sq/Ad/AdSq 7/8/1 9/6/1 0.85
Performance status, 0/1 13/3 13/3 1.00
c stage, IIB/IIIA/IIIB 3/9/4 3/13/0 0.14
Involved structures
cT3 Chest wall 7 9
Parietal pleura 3 5
Rib or muscle 4 4
Diaphragm 0 1a
Pericardium 0 2a
Mediastinal pleura 2 0
\2 cm carina 1 0
cT4 Great vessel 6a 5
Esophagus 1a 0
Superior sulcus 2 0
Operation type 0.79
Lobectomy 13 12
Sleeve lobectomy 1 0
Bilobectomy 1 1
pneumonectomy 1 3
Period of treatment, y, 1997–2003/2004–2009 7/9 9/7 0.72
Combined resection, yes/no 14/2 15/1 1.00
Chest wall 6 9b
Parietal pleura 2 6
Rib or muscle 4 3
Diaphragm 0 4b
Pericardium 0 1b
Mediastinal pleura 4 1b
Great vessel 4 3
PS propensity score, IC induction chemoradiotherapy, IS initial surgery, Sq squamous cell carcinoma, Ad adenocarcinoma, AdSq adenosquamous
carcinoma
a Multiple structures were involved: diaphragm with pericardium (n = 1), great vessel with esophagus (n = 1)
b Multiple structures were resected; chest wall with diaphragm (n = 1), with diaphragm and great vessel (n = 1), diaphragm with pericardium
(n = 1)
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potentially confounding variables, the patients in the IC
group continued to exhibit a better outcome than those in
the IS group (P = 0.00067). In addition, among 52 patients
with cN0–1 disease, 24 patients were extracted using PS
matching (Supplementary Material 6). After adjustments,
the patients in the IC group also exhibited a better outcome
those than the IS group (P = 0.026).
DISCUSSION
We previously reported that induction CRT followed by
surgery is a promising treatment for patients with stage III
NSCLC.9 The present study focused on cT3–4 LA disease
involving adjacent structures and compared the outcome of
trimodality therapy with initial surgery in this population.
Our study showed that trimodality therapy significantly
prolonged the OS and DFS times. Although the present
study was retrospective in design, a PS matching analysis
reduced the biases inherent in this series.
A significantly high incidence of postoperative compli-
cations after induction treatments has been reported,
particularly after a pneumonectomy.14 In the present study,
no treatment-related mortalities were observed in the IC
group. Although no significant difference in the rate of
postoperative complication was observed between the
groups, severe complications including bronchopleural
fistula and empyema occurred in the IC group. This out-
come suggests the importance of a meticulous surgical
procedure and perioperative management.
The rationale for the use of induction treatments is to
prevent cancer cell microresidues at local sites and to
eradicate micrometastatic disease at distant sites.15 Indeed,
the outcomes of the present study support this rationale.
First, local recurrences occurred in 11% of the patients in the
IC group and 30% in the IS group. The control of local
recurrences using induction CRT is thought to contribute to
a better likelihood of achieving a complete resection. Fur-
thermore, nodal metastasis is known to be significantly more
common among patients with visceral pleura invasion,
possibly through the subpleural lymphatics to the hilar and
mediastinal lymph nodes.16 The therapeutic effect of
induction CRT on this afferent pathway may have contrib-
uted to the better outcome of the IC group. Second, distant
metastases occurred in 17% of the patients in the IC group
and 23% of the patients in the IS group. These frequencies
are similar even though the IC group included more patients
with an advanced disease stage, compared with the IS group.
This outcome suggests the effectiveness of induction ther-
apy for eradicating distant micrometastasis.
In this study, all 13 patients with c-IIIB disease (4 of
T3N3M0 and 9 of T4N2M0) were treated with trimodal
therapy, but mediastinal nodal metastasis was only
confirmed in three patients. Recent guidelines do not rec-
ommend surgery for T4N2 or more advanced disease, nor
do they recommend induction chemotherapy or CRT fol-
lowed by surgery for N3 disease.1, 3, 17 Although the c-IIIB
stage may have been overestimated in our series, all the
c-IIIB patients were treated with trimodality therapy, and
their clinical outcomes seemed to be acceptable (3-year
survival rate of 75%).
Finally, our induction CRT regimen was thought to
contribute to the favorable outcome of the trimodality
therapy. Our regimen originated from the same combina-
tion of docetaxel and cisplatin with concurrent radiation
that is used for unresectable LA-NSCLC.18 A recent study
showed that concurrent CRT with docetaxel and cisplatin is
associated with a favorable prognosis compared with
mitomycin, vindesine, and cisplatin (MVP) in patients with
unresectable LA-NSCLC.19 Of note, Stupp et al. reported
the excellent prognosis (40% of 5-year OS rate) of stage
IIIB patients treated with trimodal therapy with docetaxel
and cisplatin.20
In conclusion, our results strongly suggest that this
combined modality treatment is highly effective in patients
with cT3–4 LA-NSCLC, compared with initial surgery.
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